Insider Selling: Regeneron Pharmaceuticals Inc (REGN) Director Sells 1,791 Shares of Stock

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Joseph L. Goldstein sold 1,791 shares of the company’s stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $410.00, for a total value of $734,310.00. Following the completion of the sale, the director now owns 14,114 shares in the company, valued at $5,786,740. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Regeneron Pharmaceuticals stock traded up $0.23 during mid-day trading on Friday, reaching $408.29. The company had a trading volume of 42,053 shares, compared to its average volume of 715,941. Regeneron Pharmaceuticals Inc has a fifty-two week low of $281.89 and a fifty-two week high of $416.49. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.04 and a quick ratio of 3.30. The firm has a market capitalization of $43.24 billion, a P/E ratio of 30.44, a P/E/G ratio of 1.72 and a beta of 1.14.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, topping analysts’ consensus estimates of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The business had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter last year, the firm earned $3.99 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 10.8% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals Inc will post 18.88 earnings per share for the current year.

Several equities analysts recently commented on REGN shares. BidaskClub upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday. Cowen reissued a “hold” rating and issued a $385.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday. TheStreet downgraded Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Tuesday, November 13th. Argus reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 13th. Finally, ValuEngine upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 15th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $404.11.

A number of institutional investors have recently added to or reduced their stakes in the stock. Rehmann Capital Advisory Group increased its holdings in Regeneron Pharmaceuticals by 1,700.0% during the 3rd quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 68 shares during the period. Signaturefd LLC increased its holdings in shares of Regeneron Pharmaceuticals by 123.8% in the 2nd quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 198 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $159,000. Columbia Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $196,000. Finally, Ingalls & Snyder LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $204,000. Institutional investors and hedge funds own 67.20% of the company’s stock.

WARNING: “Insider Selling: Regeneron Pharmaceuticals Inc (REGN) Director Sells 1,791 Shares of Stock” was posted by WKRB News and is owned by of WKRB News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.wkrb13.com/2019/01/11/insider-selling-regeneron-pharmaceuticals-inc-regn-director-sells-1791-shares-of-stock.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply